Evolving New Treatment for Myelodysplastic Syndromes

Abstract

Over the last several years, there has been substantial progress in the definition, diagnosis, and management of myelodysplastic syndromes (MDSs). This progress includes the new World Health Organization classification and the revised standardized response criteria to be applicable to most new compounds, which, taken together with the International Prognostic Scoring System, provide a uniform basis for the management of individual patients. The recent introduction of certain new agents, as well as an apparent increase in the use of stem cell transplantation with a variety of so-called reduced-intensity settings, has indeed raised the hope that we are entering a new era of MDS treatment.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the classification of the myelodysplastic syndromes.Br J Haematol. 1982;51:189–199.

    Article  CAS  Google Scholar 

  2. 2.

    Larson RA. Myelodysplasia: when to treat and how.Best Pract Res Clin Haematol. 2006;19:293–300.

    Article  Google Scholar 

  3. 3.

    Steensma DP, Bennett JM. The myelodysplastic syndromes: diagnosis and treatment.Mayo Clin Proc. 2006;81:104–130.

    Article  Google Scholar 

  4. 4.

    Lindberg EH. Strategies for biology- and molecular-based treatment of myelodysplastic syndromes.Curr Drug Targets. 2005;6:713–725.

    Article  CAS  Google Scholar 

  5. 5.

    Schiffer CA. Clinical issues in the management of patients with myelodysplasia.Hematology Am Soc Hematol Educ Program 2006:205-210.

    Article  Google Scholar 

  6. 6.

    Hamblin TJ. Epidemiology of the myelodysplastic syndromes. In: Bennett JM, ed.The Myelodysplastic Syndromes: Pathobiology and Clinical Management New York, NY: Marcel Dekker; 2002:15–27.

    Google Scholar 

  7. 7.

    Aul C, Germing U, Gatterman N, Minning H. Increasing incidence of myelodysplastic syndromes: real or fictitious?Leuk Res. 1998;22:93–100.

    Article  CAS  Google Scholar 

  8. 8.

    Fenaux P. Chromosome and molecular abnormalities in myelodysplastic syndromes.Int J Hematol. 2001;73:429–437.

    Article  CAS  Google Scholar 

  9. 9.

    Corey SJ, Minden MD, Barber DL, Kantarjian H, Wang JC, Schimmer AO. Myelodysplastic syndromes: the complexity of stem-cell diseases.Nat Rev Cancer. 2007;7:118–129.

    Article  CAS  Google Scholar 

  10. 10.

    Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms.Blood. 2002;100:2292–2302.

    Article  CAS  Google Scholar 

  11. 11.

    Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes.Blood. 1997;89:2079–2088.

    PubMed  CAS  Google Scholar 

  12. 12.

    Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia.Blood. 2006;108:419–425.

    Article  CAS  Google Scholar 

  13. 13.

    Germing U, Gattermann N, Strupp C, Aivado M, Aul C. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients.Leuk Res. 2000;24:983–992.

    Article  CAS  Google Scholar 

  14. 14.

    Cazzola M. Alternatives to conventional or myeloablative chemotherapy in myelodysplastic syndrome.Int J Hematol. 2000;72:134–138.

    PubMed  CAS  Google Scholar 

  15. 15.

    Jädersten M, Montgomery SM, Dybedal I, Porwit-McDonald A, Hellström-Lindberg E. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.Blood. 2005;106:803–811.

    Article  CAS  Google Scholar 

  16. 16.

    Molldrem JJ, Caples M, Marvoudis D,Plante M, Young NS,Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome.Br J Haematol. 1997;99:699–705.

    Article  CAS  Google Scholar 

  17. 17.

    Joná sova A, Neuwirtová R, Cermák J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow.Br J Haematol. 1998;100:304–309.

    Article  Google Scholar 

  18. 18.

    List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.N Engl J Med. 2006;355:1456–1465.

    Article  CAS  Google Scholar 

  19. 19.

    Martino P, Lacobelli S, Brand R, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes.Blood. 2006;108:836–846.

    Article  CAS  Google Scholar 

  20. 20.

    de Witte T, van Biezen A, Brand R, et al. Which myelodysplastic syndrome patients are candidates for transplantation?Leuk Res. 2006;30(Suppl 1):S21.

    Google Scholar 

  21. 21.

    Pellagatti A, Fidler C, Wainscoat JS, Boultwood J. Gene expression profiling in the myelodysplastic syndromes.Hematology. 2005;10:281–287.

    Article  CAS  Google Scholar 

  22. 22.

    Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. JNatl Compr Canc Netw. 2006;4:91–96.

    Article  CAS  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Yataro Yoshida.

About this article

Cite this article

Yoshida, Y. Evolving New Treatment for Myelodysplastic Syndromes. Int J Hematol 86, 297–300 (2007). https://doi.org/10.1532/IJH97.07026

Download citation

Key words

  • Myelodysplastic syndromes
  • Treatment
  • Classification